Armistice Capital’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$622K Hold
536,600
– – 0.01% 195
2026
Q2
$478K Hold
536,600
– – 0.01% 217
2026
Q1
$553K Buy
+536,600
New +$568K 0.01% 171

Other funds holding BCTXL

Armistice Capital's BCTXL Position: Q3 2026 in Review

Armistice Capital held its BriaCell Therapeutics Warrant expiring 2031 (BCTXL) position steady in Q3 2026 at 536,600 shares worth $622K. The position accounts for 0.01% of the portfolio, ranked #195.

Armistice Capital first reported a position in BCTXL in Q1 2026 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold BCTXL as of Q3 2026.

  • Armistice Capital held 536,600 shares of BriaCell Therapeutics Warrant expiring 2031 worth $622K as of Q3 2026.
  • Armistice Capital left its BriaCell Therapeutics Warrant expiring 2031 share count unchanged in Q3 2026.
  • BriaCell Therapeutics Warrant expiring 2031 made up 0.01% of Armistice Capital's portfolio in Q3 2026, its #195 holding.
  • Armistice Capital first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q3 2026.

Based on Armistice Capital's 13F filing for Q3 2026, filed 16 Nov 2026.